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RP–HPLC;Abstract Simultaneous determination of nimesulide, phenylpropanolamine, chlorpheniramine and
caffeine in rat plasma by reversed-phase high performance liquid-chromatography (RP–HPLC)
with photodiode array (PDA) detection method was developed and validated. Sample preparation
based on a simple extraction procedure consisting of deproteination and extraction with methanol
solution followed by volume make up with the aqueous component of the mobile phase obtained
best recoveries of the analytes. The chromatographic conditions were optimized and the analytes
were separated on XBridge C18 (3.5 lm, 4.6 · 150 mm) column in isocratic elution with the mobile
phase composition of acetonitrile and 10 mM ammonium acetate buffer (pH 4.0, 0.1% formic acid)
(18:82 v/v%) at the ﬂow rate of 1 mL min1 and the efﬂuents were monitored in the wavelength
range of 220–275 nm. The method was linear for all analytes over the following concentration
(ng mL1) ranges: nimesulide 250–4000; phenylpropanolamine 100–1500; chlorpheniramine 20–
500; and caffeine 10–100. Acceptable precision, accuracy and recoveries were obtained for quality
control (QC) samples at three concentrations (low QC, middle QC and high QC). The percentage of
relative standard deviation (% RSD) of Inter and intra-run precision of all molecules was <15%
and the percentage of accuracy was 100 ± 10. The analytes were more stable in rat plasma atlasma by
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Nimesulide (NMS) is [N-(4-Nitro-2-phenoxyphenyl) methane
sulfonamide] a relatively cyclooxygenase-2 (COX-2) selective,
non-steroidal anti-inﬂammatory drug (NSAID) with analgesic
and antipyretic properties (Rainsford, 2006).
Phenylpropanolamine (PPA) is [(1RS, 2SR)-2-amino-1-
phenylpropan-1-ol] a sympathomimetic compound, which
has been widely used as an over the counter (OTC) and pre-
scription medication for cough, cold, and nasal decongestant
(Flavahan, 2005). Chlorpheniramine (CPM) is [3-(4-chloro-
phenyl)-N, N-dimethyl-3-pyridin-2-yl-propan-1-amine] a ﬁrst-
generation alkylamine antihistamine used in the prevention
of the symptoms of allergic conditions such as rhinitis and
urticaria (Carlsson and Linqvist, 1969). Caffeine (CFN)
[1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione 3,7-dihydro 1,3,
7-trimethyl-1H-purine-2,6-dione] acts as a central nervous sys-
tem stimulant, temporarily warding off drowsiness, mood
elevator and restoring alertness (Nehlig et al., 1992). The com-
bined dosage form of NMS, PPA, CPM and CFN is more
effective in controlling common cold and severe allergichemical structure of (A) NMS, (
. et al., Simultaneous quantiﬁcation of n
o pharmacokinetic studies in healthy rcases than individual drugs (Fig. 1). Diphenylpyraline (DPP)
[4-benzhydryloxy-1-methyl-piperidine] was used as an internal
standard (IS) for determination of all these drugs in spiked rat
plasma samples. All the compounds are white, crystalline
powders and polarity nature so easily soluble in polar solvents
such as water, methanol, etc. Till to date no RP–HPLC
method has been reported for the simultaneous determination
of NMS, PPA, CPM and CFN in rat plasma. Several
methods have been reported for the determination of NMS,
PPA, CPM and CFN individually or combination with other
drugs, such as HPLC with UV/PDA detection (Kumar et al.,
2012; Nageswara Rao et al., 2005; Rolim et al., 2007 and
Pavan Kumar et al., 2006) or ﬂuorescence detection
(Fu-Ming and Chen-Wen, 2005), Liquid Chromatography–
Spectrophotometry (Hadad et al., 2007), Liquid
chromatography–mass spectrometry (LC–MS) or Liquid
chromatography-tandem mass spectrometry (LC–MS/MS)
(Bao, 2006; Zou et al., 2008; Li et al., 2010 and
Chen et al., 2004), Fourier transform-near infrared
(FT–NIR) (Ajayakumar et al., 2012), Stripping Voltammetry
(Furlanetto et al., 2000), Micellar Electrokinetic CapillaryB) PPA, (C) CFN, (D) CPM and (E) IS.
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thin layer chromatography (HPTLC) (Dhongle et al., 2011).
The four analytes are highly different polarity nature and wide
range of concentrations in plasma after an oral dose. This
method is validated and has been successfully applied to phar-
macokinetics study of compounds in six healthy Wistar rats.2. Experimental conditions
2.1. Chemical and reagents
Nimesulide (NMS), phenylpropanolamine hydrochloride
(PPA), chlorpheniramine maleate (CPM), caffeine (CFN)
and diphenylpyraline (IS) (purity > 99% for all drugs) were
gift samples from Shantha Biotechniques Ltd., Hyderabad,
India. CureX tablets (containing 100 mg NMS, 12.5 mg
PPA, 4 mg CPM and 30 mg CFN) were purchased from
Mycure pharma Pvt. Ltd (Bangalore, India) (manufactured
by Embiotic Laboratories (P) Ltd., Bangalore, India). HPLC
grade acetonitrile and methanol (Sigma Aldrich, Mumbai,
India) and analytical reagent grade (AR) ammonium acetate,
acetic acid and formic acid (SD Fine Chemicals, Mumbai,
India) (>99.5% purity) were used. Deionized water was
prepared by using a Millipore synergy (Millipore, France).
2.2. Instrumentation
The HPLC system consisting of a quaternary LC-20AD pump,
a SPD-M20A diode array detector, a SIL-20AC auto sampler,
a DGU-20A5 degasser and CBM-20A communications bus
module (all from Shimadzu, Kyoto, Japan) was used. The
pH measurements were carried out by Elico, model LI 120,
pH meter equipped with a combined glass–calomel electrode.
The chromatographic and the integrated data were recorded
using HP-Vectra (Hewlett Packard, Waldron, Germany) com-
puter system using LC-Solution data acquiring software
(Shimadzu, Kyoto, Japan). Separation and quantitation were
made on an XBridge C18 column (150 · 4.6 mm I.d, 3.5 lm
particle size) (Waters, Chromatographie technik GmbH,
Germany).
2.3. Preparation standard and quality control (QC) solutions
All stock solutions of 1000 lg mL1 of NMS, PPA, CPM and
CFN were prepared independently with mobile phase. The
solution was prepared by dissolving 100 mg of each drug in
sufﬁcient amount of mobile phase and the volume was com-
pleted to 100 mL volumetric ﬂask with the same solvent.Table 1 Concentrations of combined calibration standards (C) and
Concentration (ng mL1) NMS
C1 250
C2 (QC 1) 500
C3 750
C4 (QC 2) 1000
C5 1500
C6(QC 3) 2000
C7 4000
Concentration ranges 250–4000
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solutions, working solutions (Table 1) were prepared by serial
dilution of each sample. Three quality control samples of each
drug were prepared in lg mL1 such as 0.5, 1, 2 for NMS, 0.2,
0.6, 1 for PPA, 0.03, 0.12, 0.18 for CPM and 0.015, 0.025, 0.04
for CFN, respectively. This was presented in Table 1. A
1.0 mg mL1 stock solution of IS was used to prepare a
200 ng mL1 working IS solution. All the stock and working
standard solutions were stored at 4 C and brought to room
temperature (20 C) before use.
2.4. Sample preparation
Protein precipitation extraction method was used for prepara-
tion of plasma sample from the rat blood. The spiking 900 lL
of blank plasma sample was transferred into a 10 mL
centrifuge tube. To the above centrifuge tube 50 lL standard
solutions, 50 lL of IS (4 lg mL1) and 2 mL of methanol were
added (ﬁnal concentration of IS was made to 200 ng mL1),
then vortexed for 10 min and centrifuged at 4000 rpm for
20 min from that 100 lL of the supernatant solution was care-
fully transferred into vial and injected into HPLC system. The
unique sample was also prepared for invitro analysis by addi-
tion of 15 lL of NMS (100 lg mL1); 15 lL of PPA
(100 lg mL1); 10 lL of CPM (15 lg mL1); 10 lL of CFN
(15 lg mL1); 50 lL of IS (12 lg mL1) and 2 mL of methanol
to 900 lL of blank plasma in centrifuge tube. The ﬁnal concen-
tration was made to 500 ng mL1 of NMS and PPA,
50 ng mL1 of CPM and CFN, 200 ng mL1 of IS. This solu-
tion was vortexed and sonicated as above and supernatant
solution was injected into HPLC system. The QC samples at
three concentrations (low QC, middle QC and high QC) of
each drug were prepared in a similar fashion.
2.5. Method validation
The method was validated for selectivity, matrix effect, preci-
sion, accuracy, linearity, sensitivity, recovery and stability
according to the US Food and Drug Administration (FDA)
guidelines for the validation of bioanalytical method (FDA,
2001). The selectivity of this method was investigated by
analyzing six individual rat blank plasma samples. Each blank
sample was tested for interference using the present analytical
method and compared with spiked sample whose concentra-
tion of the analyte was at the Low Limit of Quantiﬁcation
(LLOQ). Calibration standard samples in rat plasma were pre-
pared for three separate batches. Intra (same day) and inter
(different days (10 days))-batch precision and accuracy were
evaluated by measurement of reference in plasma in ﬁvequality control (QC) solutions.
PPA CPM CFN
100 20 10
200 30 15
400 60 20
600 120 25
800 150 40
1000 380 70
1500 500 100
100–1500 20–500 10–100
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medium and high QC) for three separate batches. The matrix
effect was evaluated by adding known amounts of the analyte
to pre-treated blank plasma samples, immediately before injec-
tion (Taylor, 2005). The peak areas obtained from these assays
were compared to those of the standard solutions and the cor-
responding peak area ratios were calculated. Recovery was
determined by comparing the detector response of the pre-ex-
tracted spiked sample with those spiked post-extraction onto a
blank matrix because the analytes and IS have the same
matrix. The small variations of ﬂow rate (±0.2 mL min1),
volume of acetonitrile in mobile phase (±5 vol%), concentra-
tion of buffer (±5 mM) and pH (±1)) were studied for robust-
ness test. The stabilities of quality control samples were tested
under different storage conditions; i.e. three freeze–thaw
cycles, room temperature (at 20 C) for 24 h for short term sta-
bility and re-injection after one month (at 20 C) for long
term stability.
2.6. Animals and plasma sample preparation for
pharmacokinetic study
In vivo drug release was investigated in male Wistar rats. Six
Wistar rats (190–210 g) were procured from Mahavir enter-
prises, Hyderabad, India. The use of animals was approved
by the ‘Institutional Animal Ethical Committee’ (169/99/
CPCSEA, University College of Pharmaceutical Sciences,
Warangal, India); throughout the experimental period, the ani-
mals were housed under standard condition in cages at room
temperature (20 ± 2) C; relative humidity (60–70)% exposed
to 12/12 h light/dark cycle. They were fed with standard
laboratory diet supplied by Rayans biotechnologies Pvt Ltd.,
Hyderabad, India. Food and water was allowed ad libitum
during the experiment. The study was performed in three
groups (18 Wistar rats were divided into 3 groups (3 · 6 rats),
again these three groups were subdivided into 3 groups
(3 · 2 rats). The samples were collected in different time inter-
vals using subdivided groups. During the time of sample col-
lection 2 rats were used for 12 h, then 2 rats were used for
12–24 h and remaining 2 rats were used for 24–36 h after injec-
tion of drugs. First two groups received a single oral dose of
25 mg kg1 of standard and test solutions (combination of
pure drugs) and third group received a single oral dose of
CureX tablet. Serial blood samples were collected into the pro-
cessed test tube at variable time-points (0, 0.2, 0.5, 1, 2, 3, 5, 6,
12, 24, 36 h for PPA; 0, 0.4, 0.6, 0.8, 1.2, 2, 3, 4, 5, 6, 12, 18 h
for NMS; 0, 0.2, 0.6, 1, 1.5, 3, 3.5, 5, 7.5, 10, 12, 24 h for CPM;
0, 0.3, 0.6, 1, 1.5, 3, 6, 10, 15, 19, 24 h for CFN, respectively)
into heparinized collection tubes. Whole blood sample was
centrifuged for 20 min at 4000 rpm for assortment of rat plas-
ma and stored at 20 C. The stored plasma samples were
allowed to thaw at room temperature (20 C) before process-
ing. An aliquot (900 lL) was pipetted into a 10 mL polypropy-
lene tube, and 100 lL of IS (2 lg mL1) and 2 mL of methanol
were added (ﬁnal concentration of IS was made to
200 ng mL1). The mixture was vortex mixed brieﬂy, and cen-
trifuged at 4000 rpm for 20 min after standing for 5 min at
room temperature; that 100 lL of the supernatant solution
was carefully transferred into vial and injected into HPLC sys-
tem. Statistical analysis was performed on Microsoft Excel
2003 and pharmacokinetics parameters were calculated onPlease cite this article in press as: Ramesh, T. et al., Simultaneous quantiﬁcation of n
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ment model.
3. Results and discussion
To obtain the best chromatographic conditions, different col-
umns, mobile phases with different pH and type of organic sol-
vent were tested to provide sufﬁcient selectivity and sensitivity
in short separation time. The four analytes and IS had differ-
ent retention properties because of their different polarities
(Fig. 1). The best chromatographic conditions took place on
XBridge C18 column with mobile phase consisting of
10 mM ammonium acetate (pH 4.0, 0.1% formic acid): ace-
tonitrile (82:18% v/v) at ﬂow rate 1 mL min1 and the eluate
were monitored in the wavelength range of 220–275 nm
(Fig. 2). The inﬂuence of organic solvent concentration was
carefully studied, increasing organic solvent concentration to
improve peak shape and decrease the run time. Different pH
of buffer was used for the separation of all analytes. Finally,
pH 4.0 was chosen as the optimum value for better peak shape
and reasonable run time. Other pH conditions, PPA and CPM
were more retained on the column (the retention time of PPA
and CPM were 21.76 and 23.82 minutes, respectively) and sol-
vent consumption was also more. Diphenylpyraline was used
as internal standard (IS) applied for determination of these
drugs owing to retention characters that not affected seriously
by change of pH, so it eluted with reasonable resolution and
absorbance characters that show high absorbance at the cho-
sen wave length (234 nm) that increases the sensitivity of the
method. The proposed method succeeds in the determination
of the studied mixture in spiked plasma sample and also in real
rat plasma sample.
3.1. Method validation
The described method was validated in terms of linearity, sen-
sitivity, recovery, speciﬁcity, stability, precision and accuracy
according to FDA guidelines (FDA, 2001).
3.2. Speciﬁcity and sensitivity
The speciﬁcity of the extraction and chromatographic method
tested the ability of the method to differentiate and quantitate
the analyte in the presence of other endogenous constituents in
the sample and to detect potential interferences. No interfering
peaks were observed at the retention times of the analytes. The
LLOQ was found at 250 ng mL1 for NMS, 100 ng mL1 for
PPA, 20 ng mL1 for CPM and 10 ng mL1 for CFN. Fig. 2
shows RP–HPLC standard chromatogram of NMS, PPA,
CPM, CFN and IS; the blank rat plasma sample and the blank
plasma sample spiked with NMS, PPA, CPM, CFN and IS.
3.3. Linearity, accuracy and precision
All calibration curves were linear within the concentration
ranges tested (Table 1). Typical equations of calibration curves
and correlation coefﬁcients were as follows: NMS:
y= 280.37C + 157.84, r= 0.9982; PPA: y= 135.88C –
142.04, r= 0.9990; CPM: y= 125.72C – 68.596, r= 0.9973;
CFN: y= 227.87C + 191.24, r= 0.9986. The calibrationimesulide, phenylpropanolamine, caﬀeine and chlorpheniramine in rat plasma by
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Figure 2 Chromatograms showing: (A) chromatogram of NMS (500 ng mL1), PPA (500 ng mL1), CPM (50 ng mL1), CFN
(50 ng mL1) and IS (200 ng mL1) in mobile phase; (B) chromatogram of a blank plasma sample and (C) chromatogram of invitro blank
plasma sample spiked with above concentration of NMS, PPA, CPM, CFN and IS.
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LLOQ for ﬁve replicates were (92.87 ± 3.0)% for NMS,
(91.3 ± 7.2)% for PPA, (93.87 ± 6.8)% for CPM and
(92.71 ± 5.9)% for CFN. The relative standard deviation
(RSD) of precision values for intra-batch and inter-batch
was <15% of each QC level. The accuracy deviation values
for intra-batch and inter-batch were all within (100 ± 10)%
of the actual values at each QC level. This was shown in
Table 2, which revealed that the precision and accuracy of mix-
ture at three QC concentrations were within the acceptable
limits.
3.4. Recovery and matrix effect
Recovery was determined by comparing the detector response
of the pre-extracted spiked sample with those spiked
post-extraction onto a blank matrix because the analytes andPlease cite this article in press as: Ramesh, T. et al., Simultaneous quantiﬁcation of n
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QC concentrations were in the range of (80 ± 15)% in plasma.
The recoveries for each analyte were shown in Table 3. The
inter-subject variability of matrix effect at every concentration
level should be <15% for acceptable performance (Taylor,
2005). The matrix effect could be considered the same for
pre and post-extraction spiked samples. The matrix effect
was shown in Table 3. For all the analytes the matrix effects
were in the range of (90 ± 10)%. The results obtained were
good, since the sample/standard peak area ratios of matrix
effect were always higher than 86.7% (Table 3).
3.5. Robustness
According to the ICH guidelines (ICH, 1996) the robustness of
an analytical procedure is a measure of its capacity to remain
unaffected by small, deliberate variations in methodimesulide, phenylpropanolamine, caﬀeine and chlorpheniramine in rat plasma by
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Table 4 Robustness data of the method.
Parameter Variation Resolution (Rs) Tailing factor (Tf) Retention time (tR)
Between CFN
and NMS
Between CPM
and PPA
Tf of NMS Tf of PPA tR of CPM tR of CFN
Flow rate (mL min1) 0.8 5.82 3.58 1.11 1.37 13.71 7.05
1 4.15 3.17 1.02 1.11 14.32 7.16
1.2 4.01 2.59 1.23 1.29 14.95 8.60
Variation in pH 3 4.00 3.96 1.27 1.25 14.88 6.47
4.0 4.15 3.17 1.02 1.11 14.32 7.16
5 5.81 3.86 1.19 1.24 18.66 9.51
Concentration of buﬀer (mM) 5 6.12 5.02 1.10 1.26 19.52 8.67
10 4.15 3.17 1.02 1.11 14.32 7.16
15 5.39 4.99 1.09 1.27 15.46 7.52
Volume of acetonitrile (volume%) 13 4.86 3.11 1.19 1.20 16.81 9.06
18 4.15 3.17 1.02 1.11 14.32 7.16
23 5.27 4.34 1.17 1.29 13.91 6.88
Table 2 Accuracy and precision for the determination of NMS, PPA, CPM and CFN in rat plasma.
Analyte Intra batch (n= 5 replicates on same day) Interbatch (n= 5 replicates on 10 diﬀerent days)
Concentration
added (lg mL1)
Concentration found
(mean ± SD, lg mL1)
Accuracy (%) Precision
(%RSD)
Concentration found
(mean ± SD, lg mL1)
Accuracy (%) Precision
(%RSD)
NMS 0.5 0.463 ± 0.015 92.61 5.3 0.481 ± 0.014 96.20 5.7
1 0.927 ± 0.147 92.70 6.4 0.987 ± 0.139 98.71 6.7
2 1.951 ± 0.263 97.55 5.1 1.934 ± 0.301 96.70 4.9
PPA 0.2 0.201 ± 0.012 100.50 4.7 0.203 ± 0.018 101.50 4.8
0.6 0.598 ± 0.077 99.67 5.9 0.589 ± 0.032 98.17 5.9
1 1.039 ± 0.093 103.90 3.4 0.986 ± 0.014 98.61 2.8
CPM 0.03 0.029 ± 0.003 96.67 2.4 0.029 ± 0.004 96.67 4.3
0.12 0.118 ± 0.010 98.33 6.3 0.119 ± 0.013 99.17 6.2
0.18 0.188 ± 0.022 104.44 3.9 0.181 ± 0.017 100.56 4.8
CFN 0.015 0.014 ± 0.001 93.33 6.1 0.014 ± 0.001 93.33 6.1
0.025 0.024 ± 0.002 96.00 4.6 0.024 ± 0.003 96.00 5.5
0.040 0.041 ± 0.005 102.50 4.8 0.041 ± 0.004 102.5 4.5
Table 3 Absolute percentage of recoveries and percentage of matrix effect (%) in rat plasma
(n= 5).
Analyte Concentration
(lg mL1)
Recovery (%)
(mean ± S.D)
Matrix eﬀect, sample/standard
peak area ratio (%)
NMS 0.5 79.61 ± 5.1 89.7
1 82.23 ± 5.5 92.8
2 80.17 ± 4.9 86.7
PPA 0.2 78.56 ± 4.1 95.4
0.6 87.03 ± 4.3 96.7
1 81.51 ± 4.5 95.1
CPM 0.03 85.72 ± 6.1 94.7
0.12 90.54 ± 6.3 92.6
0.18 89.41 ± 3.8 93.2
CFN 0.015 91.03 ± 2.3 94.5
0.025 90.47 ± 1.9 91.8
0.04 89.56 ± 4.4 95.3
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Figure 3 Mean plasma concentration time proﬁle of (A) CPM, (B) NMS, (C) PPA and (D) CFN after single oral administration of
CureX tablet contains 100 mg NMS, 12.5 mg PPA, 4 mg CPM and 30 mg CFN.
Table 5 Summary of stability of NMS, PPA, CPM and CFN in rat plasma at varying conditions.
Analyte Concentration (lg mL1) Remaining percentagea (mean ± SD)
Three freeze–thaw cycles Room temperature for 24 h Re-injection after 30 days at 20 C
NMS 0.5 98.14 ± 2.1 97.11 ± 3.0 98.01 ± 3.7
1 99.25 ± 3.4 97.98 ± 5.9 97.55 ± 4.8
2 97.54 ± 4.7 96.89 ± 4.7 98.14 ± 7.6
PPA 0.2 100.19 ± 1.8 100.27 ± 2.4 98.25 ± 4.9
0.6 101.32 ± 1.1 100.48 ± 5.8 96.52 ± 6.8
1 99.78 ± 2.4 98.85 ± 2.8 97.14 ± 5.7
CPM 0.03 96.48 ± 5.6 95.82 ± 5.9 99.81 ± 6.8
0.12 98.85 ± 4.3 97.15 ± 6.7 101.21 ± 7.4
0.18 97.52 ± 3.6 96.14 ± 2.8 98.47 ± 5.8
CFN 0.015 99.0 ± 0.9 95.86 ± 8.7 102.85 ± 4.4
0.025 98.74 ± 1.5 99.29 ± 5.8 96.17 ± 2.6
0.04 98.29 ± 3.8 97.65 ± 5.1 100.26 ± 4.1
a Remaining percentage = (concentration found)/(concentration added) · 100.
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normal usage. Three different types of method parameters
exist: basic, internal and external parameters. The robustness
study was limited to investigating the inﬂuence of basic and
internal parameters. External parameters, such as different
laboratories, analysts and instruments, were not included in
the study (This study comes under ruggedness study, which
was not done). The internal parameters (Flow rate, percentage
of acetonitrile, buffer concentration and pH) were studied and
shown in Table 4. The small variation of ﬂow rate
(±0.2 mL min1), volume of acetonitrile in mobile phase
(±5 vol%), and concentration of buffer (±5 mM) and pH
(±1) were tested. The experiments were run randomly with
a plasma sample spiked with 0.5 lg mL1 of NMS,Please cite this article in press as: Ramesh, T. et al., Simultaneous quantiﬁcation of n
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j.arabjc.2015.01.0110.5 lg mL1 for PPA, 0.05 lg mL1 for CPM and
0.03 lg mL1 for CFN and IS respectively. The selected
responses (tailing factor, resolution and retention time) were
observed (Table 4) and the results indicated that the different
combinations of signiﬁcant parameters do not drastically
affect responses, so that the developed method was considered
to be robust.
3.6. Stability
The result of the stability validation was presented in Table 5.
The results revealed the ﬁnal concentration of the drugs in
each quality control samples at stability conditions i.e. three
freeze–thaw cycles, room temperature for 24 h and re-injectionimesulide, phenylpropanolamine, caﬀeine and chlorpheniramine in rat plasma by
at subjects. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/
Table 6 Pharmacokinetic parameters for four drugs after oral administration of a single oral dose containing 100 mg NMS, 12.5 mg
PPA, 4 mg CPM and 30 mg CFN.
Parameters Tmax (h) Cmax (ng mL
1) AUC0-1 (ng · h mL1) T1/2 (h) MRT (h)
NMS 0.8 ± 0.02 3591 ± 101.20 23940 ± 682.8 6.3 ± 1.3 8.3 ± 1.9
PPA 3.0 ± 0.07 450 ± 18.71 461 ± 68.34 13.2 ± 2.5 15.9 ± 3.7
CPM 1.5 ± 0.11 177 ± 13.82 375 ± 29.45 7.8 ± 1.4 8.6 ± 1.8
CFN 0.9 ± 0.03 98 ± 7.93 840 ± 43.08 6.5 ± 0.9 7.6 ± 2.1
8 T. Ramesh et al.after 30 days at 20 C. The standard deviation (SD) value
(n= 5) of ﬁnal concentration of all drugs after storing the
samples in all the stability conditions was found to be
<15%. The accuracy of stored samples was found to be nearly
equivalent to 100%. Hence, it can be inferred that all the drugs
were stable in rat plasma.
3.7. Application to pharmacokinetic study
The developed method was applied to quantify four analytes
concentration in pharmacokinetic study carried out on rats.
The mean plasma concentrations versus time proﬁle following
a single oral administration of each analyte to 3 rats was pre-
sented in Fig. 3. The important pharmacokinetic parameters
(Maximum plasma concentration (Cmax), Time required to
reach maximum plasma concentration (Tmax), Plasma half life
(t1/2), Area under curve at 24 h (AUC0ﬁ1) and Mean residence
time (MRT)) were calculated and presented in Table 6.
Therefore, the terminal phase of analytes in the study was well
characterized and the analytical assay was able to detect low
concentrations at the end of the plasma concentration time
proﬁle. The present developed HPLC assay method could be
successfully applied to the determination of all analytes in sev-
eral pharmacokinetic studies conducted in any institution.
4. Conclusions
A rapid and sensitive RP–HPLC method has been developed
for the simultaneous quantitation of NMS, PPA, CPM and
CFN in rat plasma. The method involves simple sample prepa-
ration and a short run allowing high sample throughput. The
method was found to be selective and sensitive enough to
extract and quantify these four drugs in small volume of rat
plasma. The method was found to be linear (correlation coef-
ﬁcient (r) >0.9970 for all drugs). The accuracy, precision,
speciﬁcity robustness and stability were found to be within
the acceptable limits according to FDA and ICH (for robust-
ness study) guidelines. The drug was stable in rat plasma and
also applied to adequate sensitivity for use in the pharmacoki-
netic studies. In summary it can be suitable for use in all
laboratories equipped with sophisticated or unsophisticated
instruments.Please cite this article in press as: Ramesh, T. et al., Simultaneous quantiﬁcation of n
RP–HPLC/PDA method and application to pharmacokinetic studies in healthy r
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